secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-116754
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theriva reports Q3 2023 cash of $31.2M, VCN-01 trial on track for H1 2024 enrollment completion
--------------------------------------------------------------------------------

- Cash and equivalents $31.2M as of Sept 30, 2023; expected runway into Q1 2025.
- R&D expense $4.0M in Q3 2023, up 56% from $2.6M YoY, driven by VCN-01 clinical costs.
- VIRAGE Phase 2b trial of VCN-01 in metastatic PDAC remains on track to complete enrollment in H1 2024.
- Meeting with FDA before year-end to discuss VCN-01 development pathway for pediatric retinoblastoma.
- SYN-004 Phase 1b/2a trial in HCT recipients on track for second cohort enrollment in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465923116754/0001104659-23-116754-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465923116754/tm2330262d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-116754

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer